How do we treat #VEXAS - UBA1 mutation Large multicenter cohort - 110 pts, 99% M Confirms the benefit of JAKi and tocil

Nov 14, 2023 3:10 pm
Social Author Image
https://pbs.twimg.com/profile_images/1248272740831735809/C0SA-iJf_normal.jpg
Tweet Author
bella_mehta
Social Author Name
Bella Mehta
Tweet Content
How do we treat #VEXAS - UBA1 mutation Large multicenter cohort - 110 pts, 99% M Confirms the benefit of JAKi and tocilizumab Others not so much @RheumNow #ACR23 #ACRBest #abstL03 https://t.co/tRjO31IHiD
Show on Archive Page
On
Display in Search Results
On
PDQ
Off

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2023 All Rights Reserved.

×